Unknown

Dataset Information

0

Melatonin attenuates AFB1-induced cardiotoxicity via the NLRP3 signalling pathway.


ABSTRACT: OBJECTIVE:This study was conducted to investigate the protective effect of melatonin against aflatoxin B1 (AFB1) cardiotoxicity by evaluating NOD-like receptor family pyrin domain containing protein 3 (NLRP3) signalling. METHODS:Four groups of five rats each were assessed: control group (vehicle only), two AFB1 (0.15 and 0.3 mg/kg)-treated groups, and a combined AFB1 (0.3 mg/kg) plus melatonin (5 mg/kg)-treated group. After 6 weeks of once-daily intragastric treatment, cardiac pathologic changes were observed under optical microscopy, and oxidative/antioxidative parameters were measured in myocardial homogenate. Cardiac tissue expression of NLRP3 and other important inflammasome components was also analysed. RESULTS:Compared with controls, increasing concentrations of AFB1 were associated with increased oxidative stress and caused myocardial structure damage. In addition, AFB1 dose-dependently activated the NLRP3 signalling pathway. All these indices were significantly ameliorated by combined AFB1 plus melatonin treatment versus high-dose AFB1 alone. CONCLUSION:Melatonin may reduce NLRP3 inflammasome activation by inhibiting oxidative stress and thus protect against injury from AFB1-induced myocardial toxicity.

SUBMITTER: Yan H 

PROVIDER: S-EPMC7588772 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Melatonin attenuates AFB1-induced cardiotoxicity via the NLRP3 signalling pathway.

Yan Hui H   Ge Junhua J   Gao Hongrui H   Pan Yang Y   Hao Yan Y   Li Jian J  

The Journal of international medical research 20201001 10


<h4>Objective</h4>This study was conducted to investigate the protective effect of melatonin against aflatoxin B1 (AFB1) cardiotoxicity by evaluating NOD-like receptor family pyrin domain containing protein 3 (NLRP3) signalling.<h4>Methods</h4>Four groups of five rats each were assessed: control group (vehicle only), two AFB1 (0.15 and 0.3 mg/kg)-treated groups, and a combined AFB1 (0.3 mg/kg) plus melatonin (5 mg/kg)-treated group. After 6 weeks of once-daily intragastric treatment, cardiac pat  ...[more]

Similar Datasets

| S-EPMC7131936 | biostudies-literature
| S-EPMC7224230 | biostudies-literature
| S-EPMC8506941 | biostudies-literature
| S-EPMC7558217 | biostudies-literature
| S-EPMC9001073 | biostudies-literature
| S-EPMC8449784 | biostudies-literature
| S-EPMC6615259 | biostudies-literature
| S-EPMC6081551 | biostudies-literature
| S-EPMC7247275 | biostudies-literature
| S-EPMC6348879 | biostudies-literature